Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury.

PubWeight™: 1.23‹?› | Rank: Top 10%

🔗 View Article (PMID 20498653)

Published in Lab Invest on May 24, 2010


David Hsu1, Masayuki Fukata, Yasmin G Hernandez, John P Sotolongo, Tyralee Goo, Junsuke Maki, Lory A Hayes, Ryan C Ungaro, Anli Chen, Keith J Breglio, Ruliang Xu, Maria T Abreu

Author Affiliations

1: Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, NY, USA.

Articles citing this

Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98

MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci U S A (2010) 1.73

Experimental Models of Inflammatory Bowel Diseases. Cell Mol Gastroenterol Hepatol (2015) 1.20

TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10

Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03

Total parenteral nutrition-associated lamina propria inflammation in mice is mediated by a MyD88-dependent mechanism. J Immunol (2013) 1.01

The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol (2013) 1.00

Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS One (2012) 0.99

Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol (2014) 0.91

Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol (2014) 0.89

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene (2015) 0.85

Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer (2015) 0.83

Amphiregulin stimulates liver regeneration after small-for-size mouse liver transplantation. Am J Transplant (2012) 0.83

Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease. World J Gastroenterol (2014) 0.83

Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci Transl Med (2014) 0.82

MyD88 adaptor-like (Mal) functions in the epithelial barrier and contributes to intestinal integrity via protein kinase C. Mucosal Immunol (2013) 0.82

Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal. Proc Natl Acad Sci U S A (2015) 0.82

TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways. FASEB J (2015) 0.81

Neisseria gonorrhoeae infection induces altered amphiregulin processing and release. PLoS One (2011) 0.79

EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice. Sci Rep (2016) 0.79

The Viral Mimetic Polyinosinic:Polycytidylic Acid Alters the Growth Characteristics of Small Intestinal and Colonic Crypt Cultures. PLoS One (2015) 0.78

The anti-inflammatory effect and potential mechanism of cardamonin in DSS-induced colitis. Am J Physiol Gastrointest Liver Physiol (2015) 0.78

Stress-induced neuroprotective effects of epiregulin and amphiregulin. PLoS One (2015) 0.78

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. Oncogene (2015) 0.78

The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia. Oncotarget (2015) 0.76

Renal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury. Am J Physiol Renal Physiol (2014) 0.76

Helicobacter pylori-induced gastric mucosal TGF-α ectodomain shedding and EGFR transactivation involves Rac1/p38 MAPK-dependent TACE activation. Inflammopharmacology (2015) 0.76

Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer. Cancers (Basel) (2011) 0.75

CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis. Mucosal Immunol (2015) 0.75

Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin. Inflammopharmacology (2017) 0.75

Articles by these authors

Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28

Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99

TLR signaling in the gut in health and disease. J Immunol (2005) 3.51

Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98

Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96

Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35

Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20

Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16

Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93

Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89

Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78

The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75

Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73

Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62

GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57

Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53

A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52

Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43

An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42

The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci (2013) 1.40

A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39

Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun (2008) 1.34

Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33

Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28

NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19

AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem (2009) 1.17

Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16

An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis (2004) 1.15

Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14

Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci (2009) 1.14

Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14

Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14

Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12

Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2006) 1.12

Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10

TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10

Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res (2002) 1.10

A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07

The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05

Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol (2003) 1.04

Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J Exp Med (2011) 1.02

Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02

Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 1.01

Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01

Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01

Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol (2012) 1.00

Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions. Hum Pathol (2010) 0.99

Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99

Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord (2005) 0.98

Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2009) 0.97

Benign hybrid perineurioma-schwannoma in the colon. A case report. Ann Diagn Pathol (2006) 0.97

Microcarcinoids in large intestinal adenomas. Am J Surg Pathol (2006) 0.95

Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94

Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93

Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol (2012) 0.93

The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93

Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells. Clin Exp Metastasis (2005) 0.92

Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med (2010) 0.90

Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest (2013) 0.88

Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87

Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease. Virchows Arch (2011) 0.87

Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol (2004) 0.87